Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Autolus Therapeutics	SQZ Biotechnologies	Aptose Biosciences	Outlook Therapeutics	Innate Pharma
Symbol	NASDAQ:AUTL	NYSE:SQZ	NASDAQ:APTO	NASDAQ:OTLK	NASDAQ:IPHA
Price Information
Current Price	$5.30	$12.46	$5.03	$1.76	$4.40
52 Week Range	Buy	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.3	1.7	1.4	1.6	1.1
Analysis Score	3.4	3.5	3.5	3.5	3.1
Community Score	2.4	4.3	2.7	2.8	2.2
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	0.8	1.7	0.0
Earnings & Valuation Score	0.6	0.6	0.0	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$21.71	$38.33	$11.63	$6.33	$8.25
% Upside from Price Target	309.70% upside	207.65% upside	131.11% upside	259.85% upside	87.50% upside
Trade Information
Market Cap	$276.91 million	$353.95 million	$454.86 million	$315.96 million	$347.56 million
Beta	1.75	N/A	1.62	0.46	N/A
Average Volume	756,222	168,282	3,838,574	4,252,815	37,641
Sales & Book Value
Annual Revenue	$2.91 million	N/A	N/A	$8.15 million	$96.12 million
Price / Sales	95.34	N/A	N/A	37.49	3.62
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$5.67 per share	N/A	$1.23 per share	$0.02 per share	$3.18 per share
Price / Book	0.93	N/A	N/A	88.00	1.38
Profitability
Net Income	$-123,850,000.00	N/A	$-26,280,000.00	$-35,240,000.00	$-23,250,000.00
EPS	($2.88)	N/A	($0.52)	($0.67)	($0.34)
Trailing P/E Ratio	N/A	0.00	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	∞	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-8,652.90%	N/A	N/A	N/A	N/A
Return on Equity (ROE)	-54.01%	N/A	-49.53%	N/A	N/A
Return on Assets (ROA)	-44.19%	N/A	-46.65%	-148.04%	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	0.33%	0.08%
Current Ratio	7.43%	N/A	24.60%	1.13%	1.99%
Quick Ratio	7.43%	N/A	24.60%	1.13%	N/A
Ownership Information
Institutional Ownership Percentage	22.86%	N/A	52.22%	3.04%	2.13%
Insider Ownership Percentage	N/A	N/A	6.30%	4.00%	N/A
Miscellaneous
Employees	376	101	31	8	247
Shares Outstanding	52.35 million	27.87 million	88.84 million	173.61 million	78.99 million
Next Earnings Date	5/6/2021 (Estimated)	6/17/2021 (Estimated)	5/4/2021 (Estimated)	5/21/2021 (Estimated)	N/A
Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF APRIL 1, 2021 finance.yahoo.com - April 19 at 5:32 AM
	SVB Leerink Comments on Innate Pharma S.A.'s FY2021 Earnings (NASDAQ:IPHA) americanbankingnews.com - April 9 at 8:37 AM
	SVB Leerink Equities Analysts Reduce Earnings Estimates for Innate Pharma S.A. (NASDAQ:IPHA) americanbankingnews.com - April 8 at 8:14 AM
	Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Up 53.1% in March americanbankingnews.com - March 31 at 2:36 PM
	SVB Leerink Raises Innate Pharma (NASDAQ:IPHA) Price Target to $7.00 americanbankingnews.com - March 25 at 9:00 AM
	Number of shares and voting rights of Innate Pharma as of February 1, 2021 finance.yahoo.com - February 24 at 1:16 AM
	Investigation announced for Investors in shares of Innate Pharma S.A. (NASDAQ: IPHA) over potential Wrongdoing openpr.com - February 11 at 2:37 PM
	Innate Pharma advances lacutamab clinical development program finance.yahoo.com - February 9 at 1:07 AM
	Innate Pharma: Attractive Price, But Comes With Uncertainty seekingalpha.com - January 30 at 11:51 PM
	Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development apnews.com - January 6 at 8:57 AM
	IPHA Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Innate Pharma S.A. Investors of Class Action and Lead Plaintiff bloomberg.com - December 23 at 2:09 PM
	IPHA Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Innate Pharma S.A. Investors of Class Action and Lead Plaintiff Deadline: December 22, 2020 businesswire.com - December 21 at 12:25 PM
	FINAL DEADLINE THIS WEEK: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm finance.yahoo.com - December 20 at 3:12 PM
	IPHA Deadline Alert: Rosen, A Trusted and Top Ranked Law Firm, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHA finance.yahoo.com - December 19 at 5:30 PM
	DEC. 22 DEADLINE: Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of ... apnews.com - December 19 at 7:29 AM
	IPHA LOSS ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Innate Pharma S.A. Investors to Seek Counsel Before Important December 22 Deadline in Securities Class Action – IPHA finance.yahoo.com - December 18 at 9:28 PM
	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Innate Pharma S.A. and Encourages Investors to Contact the Firm finance.yahoo.com - December 18 at 9:28 PM
	DEC. 22 DEADLINE: Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action – IPHA benzinga.com - December 18 at 4:28 PM
	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA) finance.yahoo.com - December 18 at 11:27 AM
	ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHA finance.yahoo.com - December 15 at 8:19 PM
	Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action – IPHA benzinga.com - December 13 at 12:12 AM
	Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action - IPHA marketwatch.com - December 11 at 6:49 PM
	SHAREHOLDER DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm finance.yahoo.com - December 11 at 6:49 PM
	Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action – IPHA finance.yahoo.com - December 11 at 1:48 PM
	Innate To Return US & EU Commercialization Rights Of Lumoxiti To AstraZeneca - Quick Facts nasdaq.com - December 11 at 3:48 AM

Date	Company	Brokerage	Action
3/16/2021	Autolus Therapeutics	Redburn Partners	Reiterated Rating
1/29/2021	Autolus Therapeutics	JPMorgan Chase & Co.	Downgrade
1/7/2021	Autolus Therapeutics	Truist	Lower Price Target
1/7/2021	Autolus Therapeutics	HC Wainwright	Lower Price Target
1/6/2021	Autolus Therapeutics	Mizuho	Reiterated Rating
12/8/2020	Autolus Therapeutics	Needham & Company LLC	Reiterated Rating
9/23/2020	Autolus Therapeutics	William Blair	Reiterated Rating
7/22/2020	Autolus Therapeutics	SunTrust Banks	Initiated Coverage
6/17/2020	Autolus Therapeutics	Jefferies Financial Group	Reiterated Rating
3/30/2021	SQZ Biotechnologies	Brookline Capital Management	Reiterated Rating
1/7/2021	SQZ Biotechnologies	Evercore ISI	Initiated Coverage
11/24/2020	SQZ Biotechnologies	Stifel Nicolaus	Initiated Coverage
11/24/2020	SQZ Biotechnologies	Bank of America	Initiated Coverage
11/24/2020	SQZ Biotechnologies	BTIG Research	Initiated Coverage
3/30/2021	Aptose Biosciences	Oppenheimer	Boost Price Target
2/22/2021	Aptose Biosciences	Jonestrading	Initiated Coverage
10/20/2020	Aptose Biosciences	Canaccord Genuity	Reiterated Rating
10/19/2020	Aptose Biosciences	Cantor Fitzgerald	Initiated Coverage
9/22/2020	Aptose Biosciences	Alliance Global Partners	Initiated Coverage
6/23/2020	Aptose Biosciences	Piper Sandler	Reiterated Rating
6/12/2020	Aptose Biosciences	Maxim Group	Initiated Coverage
5/23/2019	Aptose Biosciences	Roth Capital	Reiterated Rating
3/1/2019	Aptose Biosciences	Royal Bank of Canada	Initiated Coverage
1/25/2019	Aptose Biosciences	Citigroup	Initiated Coverage
2/17/2021	Outlook Therapeutics	LADENBURG THALM/SH SH	Reiterated Rating
5/16/2019	Outlook Therapeutics	CIBC	Initiated Coverage
4/22/2019	Outlook Therapeutics	Ascendiant Capital Markets	Initiated Coverage
3/25/2021	Innate Pharma	SVB Leerink	Boost Price Target
11/23/2020	Innate Pharma	The Goldman Sachs Group	Initiated Coverage
9/9/2020	Innate Pharma	Bryan, Garnier & Co	Downgrade

(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources